Advicenne S.A. (ADVIC.PA)

6.5 €

0.00 (-%)
Rating:
Recommendation:
-
Symbol ADVIC.PA
Price 6.5 €
Beta 1.432
Volume Avg. 0.05M
Market Cap 64.509M
Shares () -
52 Week Range 3.73-14.3
1y Target Est -
DCF Unlevered ADVIC.PA DCF ->
DCF Levered ADVIC.PA LDCF ->
ROE -
ROA -
Operating Margin -
Debt / Equity 164.12% Buy
P/E -
P/B -
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Dr. Andr Ulmann M.D., Ph.D.
Healthcare
Biotechnology
Paris

Advicenne S.A. develops therapeutics for the treatment of rare kidney diseases. Its lead product candidate is ADV7103 for the treatment of distal renal tubular acidosis in children and adults, as well as for the treatment of cystinuria, an inherited renal tubulopathy. The company also provides ADV6209, an oral liquid solution for children to reduce anxiety and to improve their immobility. Advicenne S.A. was founded in 2007 and is based in Paris, France.